Omega-3 Recommendations Updated: High-Dose Icosapent Ethyl for High-Risk Patients
European Atherosclerosis Society has shared a post on LinkedIn:
“The recommendation for the use of omega 3 polyunsaturated fatty acids from 2019 has changed in the Focussed Update by now explicitly stating that only high-dose icosapent ethyl should be considered for high-risk or very high-risk patients with elevated triglyceride levels.
The rationale for this revision was the negative STRENGTH trial which failed to demonstrate benefit of a combined EPA and DHA preparation which is in contrast to the REDUCE-it trial which showed a reduction in cardiovascular events in high risk patients with TG levels of 1,5-5,6 mmol/L with icosapent ethyl which is a pure EPA compound.
Moreover there is a new recommendation for patients with severe hypertriglyceridaemia due to familial chylomicronaemia syndrome based on the results of the randomized placebo controlled APPROACH trial which showed a 77% decrease in TG levels and reduction of pancreatitis in FCS patients treated with Volanesorsen an antisense Oligoligonucleotide targeting apoC3.
This led to the recommendation that volenasoren should be considered in FCS patients with severe hypertriglyceridemia to lower triglyceride levels and reduce the risk of pancreatitis.”
Learn more here.
Discover more on Hemostasis Today.
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 2, 2025, 14:14Nihar Desai: Post-Transplant Dysphagia
-
Nov 2, 2025, 14:13Zia Choudhry Launchs a New Digital Education Platform Designed to Inform and Empower People Living With wAIHA
-
Nov 2, 2025, 14:13Rahul Bhargava: Landmark Study Shows Excellent Outcomes in Pediatric AML Transplant
-
Nov 2, 2025, 10:17ESO: Register for the Live WSC 2025 Highlights Webinar
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Nov 2, 2025, 14:15Raul Santos: Waist-to-Height Ratio and Coronary Artery Calcium Incidence
-
Nov 2, 2025, 14:12Steven AR Murphy: Urolithin A Shows Immune Rejuvenation and Mitochondrial Benefits in New Trial
-
Nov 2, 2025, 10:31Cihan Ay and RIETE Investigators Team Present External Validation of the VTE-PREDICT Score
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry
-
Nov 2, 2025, 10:03Mark Stoffels: A Stroke Can Change Lives in an Instant, But With Timely Expert Care Recovery is Possible
-
Nov 2, 2025, 09:43Louise Bannon Celebrates Barbara Adams Krolak’s 10-Year Anniversary at ISTH
-
Nov 2, 2025, 08:06Sanam Loghavi Recognized at Inaugural Women in Hematology U.S. Focus Meeting 2025